Q2 2020 Earnings Estimate for Enanta Pharmaceuticals Inc Issued By Oppenheimer (NASDAQ:ENTA)

Share on StockTwits

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) – Research analysts at Oppenheimer cut their Q2 2020 earnings estimates for shares of Enanta Pharmaceuticals in a note issued to investors on Monday, February 10th. Oppenheimer analyst J. Olson now expects that the biotechnology company will post earnings per share of ($0.83) for the quarter, down from their prior estimate of ($0.71). Oppenheimer also issued estimates for Enanta Pharmaceuticals’ Q3 2020 earnings at ($0.81) EPS, Q4 2020 earnings at ($0.61) EPS, FY2020 earnings at ($1.57) EPS, FY2021 earnings at ($3.84) EPS, FY2022 earnings at ($5.90) EPS, FY2023 earnings at ($6.71) EPS and FY2024 earnings at ($5.58) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Thursday, February 6th. The biotechnology company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.06. Enanta Pharmaceuticals had a return on equity of 7.39% and a net margin of 18.00%. The firm had revenue of $52.57 million for the quarter, compared to analyst estimates of $58.75 million. During the same period in the prior year, the firm posted $1.25 EPS. The company’s revenue for the quarter was down 24.8% on a year-over-year basis.

A number of other research analysts have also commented on ENTA. JMP Securities lowered Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Friday, November 22nd. BidaskClub raised Enanta Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, February 6th. ValuEngine raised Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Finally, Zacks Investment Research lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 3rd. Three analysts have rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $96.50.

Shares of NASDAQ ENTA opened at $51.89 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 23.02 and a quick ratio of 17.77. The stock’s fifty day moving average price is $57.20 and its two-hundred day moving average price is $63.50. Enanta Pharmaceuticals has a one year low of $51.00 and a one year high of $106.80. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of 32.03 and a beta of 0.85.

In other news, CFO Paul J. Mellett sold 10,000 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $60.88, for a total transaction of $608,800.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 10.93% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC raised its position in shares of Enanta Pharmaceuticals by 43.5% during the fourth quarter. Cubist Systematic Strategies LLC now owns 8,021 shares of the biotechnology company’s stock worth $496,000 after acquiring an additional 2,433 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in shares of Enanta Pharmaceuticals by 11.9% during the fourth quarter. UBS Asset Management Americas Inc. now owns 13,004 shares of the biotechnology company’s stock worth $803,000 after acquiring an additional 1,385 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of Enanta Pharmaceuticals by 20.2% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 85,787 shares of the biotechnology company’s stock worth $5,300,000 after acquiring an additional 14,413 shares during the last quarter. Marshall Wace LLP raised its position in shares of Enanta Pharmaceuticals by 5.0% during the fourth quarter. Marshall Wace LLP now owns 181,055 shares of the biotechnology company’s stock worth $11,186,000 after acquiring an additional 8,682 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Enanta Pharmaceuticals by 22.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 334,833 shares of the biotechnology company’s stock worth $20,686,000 after acquiring an additional 61,509 shares during the last quarter. 89.32% of the stock is currently owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Further Reading: Buy-Side Analysts

Earnings History and Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.